Clinical presentation and prognosis in MOG-antibody disease: a UK study

Juryńczyk, Maciej; Messina, Silvia; Woodhall, Mark; Raza, Naheed; Everett, Rosie; Roca-Fernández, Adriana; Tackley, George; Hamid, Shahd; Sheard, Angela; Reynolds, Gavin; Chandratre, S; Hemingway, Cheryl; Jacob, Anu; Vincent, Angela; Leite, Maria Isabel; Waters, Patrick; Palace, Jacqueline

doi:10.1093/brain/awx276

Cited by 586 publications

(855 citation statements)

References 22 publications

Supporting

Mentioning

706

Contrasting

Unclassified

Order By: Relevance

“…ADEM is a typical onset presentation of MOG antibody disease in children (around 40% in the UK study), particularly in young children (70% in <8 years old), but might also occur in adults (9%) 16. Around 60% of children with ADEM have MOG antibodies 21.…”

Section: Introductionmentioning

confidence: 88%

“…Figure 2 shows the distribution of onset presentation from a recent large UK study 16. Isolated optic neuritis is the most common onset presentation (55%–64%), with simultaneous bilateral involvement in 34%–44% 16 18 19.…”

Section: Introductionmentioning

confidence: 99%

“…Onset attack breakdown in MOG antibody patients from a large UK study including 252 patients 16. ADEM, acute demyelinating encephalomyelitis; LETM, longitudinally extensive transverse myelitis; MOG, myelin oligodendrocyte glycoprotein; ON, optic neuritis; TM, transverse myelitis.…”

Section: Introductionmentioning

confidence: 99%

“…Residual bladder, bowel and sexual dysfunction are common, but only a minority of patients have a permanent disability (around 5% cannot walk 100 m unaided) 16. A patient with disproportionate sphincter and erectile disability with good motor recovery following transverse myelitis should have MOG antibodies assayed.…”

Section: Introductionmentioning

confidence: 99%

“…Patients with LETM most often relapse with optic neuritis (70% of subsequent relapses),16 and if that happens or if they have simultaneous LETM and optic neuritis (around 10% at onset) they satisfy the most recent NMOSD criteria.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations

et al. 2018

Self Cite

View full text Add to dashboard Cite

The field of central nervous system (CNS) inflammatory diseases has recently broadened to include a new condition associated with pathogenic serum antibodies against myelin oligodendrocyte glycoprotein (MOG). This is distinct from multiple sclerosis (MS) and aquaporin-4 (AQP4) antibody neuromyelitis optica spectrum disorders (NMOSD). MOG antibody-associated disease phenotypes are varied and range from classical neuromyelitis optica to acute demyelinating encephalomyelitis and cortical encephalitis. The diagnosis depends on using a reliable, specific and sensitive assay of the antibody. Clinical and imaging features of MOG-associated syndromes overlap with AQP4 antibody NMOSD but can be usually distinguished from MS: in particular, the silent lesions typical of MS that progressively increase lesion volume are rare in MOG antibody disease. The disease can relapse but medium-term immunosuppression appears to be protective. Permanent disability, particularly severe ambulatory and visual disability, is less frequent than in AQP4 antibody NMOSD and usually results from the onset attack. However, sphincter and sexual dysfunction after a transverse myelitis is common. Here we review the practical aspects of diagnosing and managing a patient with MOG antibody-associated disease.

show abstract

Section: Introductionmentioning

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder

et al. 2021

Self Cite

View full text Add to dashboard Cite

IMPORTANCEIn multiple sclerosis, magnetic resonance imaging (MRI) new silent lesions contribute to the diagnostic criteria, have prognostic value, and are used in treatment monitoring; but in aquaporin-4 antibody neuromyelitis optica spectrum disorder (AQP4-NMOSD), they are rare between attacks. Their frequency and their association with relapses in adults with myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are still unclear. OBJECTIVE To examine the frequency and characteristics of MRI new silent lesions in MOGAD and AQP4-NMOSD.

show abstract

Clinical presentation and prognosis in MOG-antibody disease: a UK study

Cited by 586 publications

References 22 publications

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations

Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease

Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder

Contact Info

Product

Resources

About